National Cancer Institute awards
Privo a $2.5M grant to optimize it lead product and prepare for its IND.
Related Posts
12Nov
Privo Technologies receives $3M Bridge Award from the National Cancer Institute (NCI).
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
10Dec
Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer
Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo’s PRV Platform... read more
12Aug
Privo Technologies, Inc. Receives 3rd U.S. FDA Orphan Drug Designation
Peabody, MA – Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug... read more
19Aug
Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting
PEABODY, Mass., June 3, 2021 -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more
03Nov
Privo receives Orphan Designation from the Food and Drug Administration.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more
02Dec
MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.
Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more
26Jan
Privo Technologies Successfully Completes Phase 1/2 Study of PRV211 Intraoperative Chemotherapy for Head and Neck Cancer Patients Novel Surgical Innovation Demonstrates Excellent Safety Profile with Potential to Reduce Tumor Recurrence
BOSTON, January 23, 2026 – Privo Technologies, Inc. today announced the successful completion of its Phase 1/2 clinical evaluation of... read more
25Feb
Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors
Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more
07Dec
Privo Technologies, Inc. To Attend Biotech Showcase January 17 to January 19, 2022
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on... read more
09Sep
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more
- © UX Strategy & Digital Branding
